019170.KS
Shin Poong Pharm.Co.,Ltd. [019170.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
019170.KS Stock Summary
Top 10 Correlated ETFs
019170.KS
Top 10 Correlated Stocks
019170.KS
In the News
019170.KS Financial details
Company Rating
-
Market Cap
675.01B
Income
-57.31B
Revenue
200.23B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
828
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-16.29
Forward P/E
-
PEG
-2.61
P/S
3.29
P/B
2.19
P/C
-
P/FCF
-16.46
Quick Ratio
-
Current Ratio
2.97
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.12K
EPS next Y
-
EPS next Q
-
EPS this Y
62.35%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
1.08%
Revenue Q/Q
0.97%
EPS Q/Q
312.84%
-
-
-
-
SMA20
2.88%
SMA50
-11.83%
SMA100
-28.63%
Inst Own
-
Inst Trans
-
ROA
-11%
ROE
-13%
ROC
-0.13%
Gross Margin
40%
Oper. Margin
-20%
Profit Margin
-20%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9560.0-22950.0
52W High
-65.49%
52W Low
-17.15%
RSI
56.74
Rel Volume
0.29
Avg Volume
727.8K
Volume
212.17K
Perf Week
7.17%
Perf Month
8.94%
Perf Quarter
-28.2%
Perf Half Y
-27.21%
-
-
-
-
Beta
0.927
-
-
Volatility
196.23%, 309.78%
Prev Close
2.72%
Price
7920
Change
1.67%
Company Profile
- Volume Average 727.8K
- Market Capitalization 675.01B
- Employee 828
- CEO Mr. Chang-Kyun Kim
- Headquarters Seoul,KR
- IPO Date 2000-01-04
-
Website
https://shinpoong.co.kr 
Shin Poong Pharm.Co.,Ltd. manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products. It also provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; and over the counter products. The company also exports its products to approximately 50 countries. Shin Poong Pharm.Co.,Ltd. was founded in 1962 and is headquartered in Seoul, South Korea.
